- United Kingdom
- /
- Healthtech
- /
- AIM:CRW
Exploring High Growth Tech Stocks in the United Kingdom for September 2024
Reviewed by Simply Wall St
London’s premier FTSE 100 index recently closed lower, reflecting concerns over weak trade data from China and its impact on global markets. In this challenging economic environment, identifying high-growth tech stocks in the United Kingdom requires a focus on companies with strong fundamentals and innovative potential.
Top 10 High Growth Tech Companies In The United Kingdom
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
STV Group | 13.15% | 46.78% | ★★★★★☆ |
Gaming Realms | 11.57% | 22.07% | ★★★★★☆ |
YouGov | 14.29% | 29.79% | ★★★★★☆ |
Facilities by ADF | 52.00% | 144.70% | ★★★★★☆ |
Redcentric | 4.89% | 63.79% | ★★★★★☆ |
Windar Photonics | 63.60% | 126.92% | ★★★★★☆ |
IQGeo Group | 11.49% | 63.61% | ★★★★★☆ |
Beeks Financial Cloud Group | 24.63% | 57.95% | ★★★★★☆ |
Oxford Biomedica | 20.98% | 106.13% | ★★★★★☆ |
Vinanz | 113.60% | 125.86% | ★★★★★☆ |
Click here to see the full list of 47 stocks from our UK High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Craneware (AIM:CRW)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Craneware plc, with a market cap of £803.93 million, develops, licenses, and supports computer software for the healthcare industry in the United States.
Operations: Craneware plc generates revenue primarily through its healthcare software segment, which brought in $189.27 million. The company focuses on developing, licensing, and supporting computer software tailored for the U.S. healthcare industry.
Craneware, a UK-based tech firm, has demonstrated robust financial performance with a notable 26.8% earnings growth over the past year, outpacing the Healthcare Services industry's 9.3%. This growth trajectory is expected to continue with earnings forecasted to rise by 25.6% annually. Additionally, the company's strategic emphasis on R&D is evident as they channel significant investments into innovation; this aligns with their recent collaborations like the one with Microsoft which leverages Azure’s cloud and AI capabilities to enhance healthcare solutions. These initiatives not only underscore Craneware’s commitment to advancing technology in healthcare but also position it well for sustained growth in an evolving industry landscape.
- Take a closer look at Craneware's potential here in our health report.
Review our historical performance report to gain insights into Craneware's's past performance.
Nexxen International (AIM:NEXN)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Nexxen International Ltd. offers a comprehensive software platform for advertisers to connect with publishers in Israel, with a market cap of £415.13 million.
Operations: Nexxen International Ltd. generates revenue primarily through its marketing services, amounting to $339.02 million. The company provides an end-to-end software platform facilitating advertiser-publisher connections in Israel.
Nexxen International, amid a challenging tech landscape, has shown resilience with an 8.8% revenue growth forecast per year, outpacing the UK market's average of 3.8%. This growth is supported by strategic partnerships like the one with The Trade Desk, enhancing cross-channel targeting capabilities through exclusive ACR data segments. Moreover, Nexxen's commitment to innovation is evident in its R&D spending trends which are crucial for sustaining its competitive edge in the rapidly evolving tech sector. Recently, the company also bolstered investor confidence by repurchasing shares worth $3.7 million, signaling strong future prospects and management’s belief in its intrinsic value.
Capita (LSE:CPI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Capita plc offers consulting, digital, and software products and services to private and public sector clients in the UK and internationally, with a market cap of approximately £343.10 million.
Operations: Capita plc generates revenue primarily through its Capita Experience (£1.12 billion) and Capita Public Service (£1.49 billion) segments, serving both private and public sectors in the UK and internationally. The company has a market cap of approximately £343.10 million.
Capita, navigating a competitive tech landscape, has demonstrated a strategic pivot by securing an extended contract worth £48 million to manage the Royal Mail Statutory Pension Scheme. This move underscores its commitment to integrating advanced digital solutions like Microsoft Dynamics into its service offerings. Despite a modest revenue growth forecast of 1.5% per year, which trails the UK market average of 3.8%, Capita's recent shift from a net loss to reporting net income of £53 million highlights operational improvements and potential for future profitability. The firm's focus on enhancing service delivery through technological upgrades is evident in its R&D expenditure trends, positioning it well for sustained advancements in the professional services sector.
- Navigate through the intricacies of Capita with our comprehensive health report here.
Explore historical data to track Capita's performance over time in our Past section.
Taking Advantage
- Unlock more gems! Our UK High Growth Tech and AI Stocks screener has unearthed 44 more companies for you to explore.Click here to unveil our expertly curated list of 47 UK High Growth Tech and AI Stocks.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About AIM:CRW
Craneware
Develops, licenses, and supports computer software for the healthcare industry in the United States.
Reasonable growth potential with proven track record.